PURPOSE: Cancer cachexia impacts on treatment options, quality of life and survival. New treatments are emerging but need to be assessed using outcomes which patients find meaningful. One approach is the measurement of physical activity levels by small lightweight monitors, but experience is limited in cancer patients. MATERIALS AND METHODS: This study formally assessed the acceptability of wearing an ActivPAL™ monitor for 1 week using compliance based on analysis of movement data. The optimal period of monitoring was explored by comparing mean values of daily step count and energy expenditure (EE) for 2 or 4 and 6 days of monitoring. The relationships between step count, stepping EE and non-stepping EE were also explored. RESULTS: Sixty patients (mean age 68 years; Eastern Cooperative Oncology Group performance status 0-2) with lung or upper gastrointestinal cancer took part. All but one found that the monitor acceptable and mean [95% CI] compliance was 98% [94-100%]. Median daily step counts and EE scores over 2 or 4 days were significantly higher than those from 6 days (p ≤ 0.01). Step count was strongly related to stepping and non-stepping EE (r = -0.911, p < 0.01). CONCLUSIONS: The ActivPAL™ is acceptable to patients with outcomes obtained over 6 days recommended for use in future studies.
PURPOSE:Cancer cachexia impacts on treatment options, quality of life and survival. New treatments are emerging but need to be assessed using outcomes which patients find meaningful. One approach is the measurement of physical activity levels by small lightweight monitors, but experience is limited in cancerpatients. MATERIALS AND METHODS: This study formally assessed the acceptability of wearing an ActivPAL™ monitor for 1 week using compliance based on analysis of movement data. The optimal period of monitoring was explored by comparing mean values of daily step count and energy expenditure (EE) for 2 or 4 and 6 days of monitoring. The relationships between step count, stepping EE and non-stepping EE were also explored. RESULTS: Sixty patients (mean age 68 years; Eastern Cooperative Oncology Group performance status 0-2) with lung or upper gastrointestinal cancer took part. All but one found that the monitor acceptable and mean [95% CI] compliance was 98% [94-100%]. Median daily step counts and EE scores over 2 or 4 days were significantly higher than those from 6 days (p ≤ 0.01). Step count was strongly related to stepping and non-stepping EE (r = -0.911, p < 0.01). CONCLUSIONS: The ActivPAL™ is acceptable to patients with outcomes obtained over 6 days recommended for use in future studies.
Authors: Max Dahele; Richard J E Skipworth; Lucy Wall; Anne Voss; Tom Preston; Kenneth C H Fearon Journal: J Pain Symptom Manage Date: 2007-03-23 Impact factor: 3.612
Authors: David R Paul; Matthew Kramer; Kim S Stote; Karen E Spears; Alanna J Moshfegh; David J Baer; William V Rumpler Journal: BMC Med Res Methodol Date: 2008-06-09 Impact factor: 4.615
Authors: Shuichi Sato; Song Gao; Melissa J Puppa; Matthew C Kostek; L Britt Wilson; James A Carson Journal: Med Sci Sports Exerc Date: 2019-09 Impact factor: 5.411
Authors: Siobhan M Phillips; Lisa Cadmus-Bertram; Dori Rosenberg; Matthew P Buman; Brigid M Lynch Journal: Am J Prev Med Date: 2017-11-06 Impact factor: 5.043
Authors: Payton Solk; Kara Gavin; Jason Fanning; Whitney Welch; Gillian Lloyd; Alison Cottrell; Anne Nielsen; Cesar A Santa Maria; William Gradishar; Seema A Khan; Swati Kulkarni; Juned Siddique; Siobhan M Phillips Journal: Qual Life Res Date: 2019-09-06 Impact factor: 4.147
Authors: Siobhan M Phillips; Whitney A Welch; Jason Fanning; Cesar A Santa-Maria; Kara L Gavin; Lisa A Auster-Gussman; Payton Solk; Marilyn Lu; Erin Cullather; Seema A Khan; Swati A Kulkarni; William Gradishar; Juned Siddique Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-09-29 Impact factor: 4.254
Authors: Catherine L Granger; Christine F McDonald; Selina M Parry; Cristino C Oliveira; Linda Denehy Journal: BMC Cancer Date: 2013-03-20 Impact factor: 4.430